Duyuru • Apr 09
Phio Pharmaceuticals Corp. has filed a Follow-on Equity Offering in the amount of $6.36 million. Phio Pharmaceuticals Corp. has filed a Follow-on Equity Offering in the amount of $6.36 million.
Security Name: Common Stock
Security Type: Common Stock
Transaction Features: At the Market Offering New Risk • Feb 10
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 20% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (125% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$9.69m market cap). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$12m net loss in 2 years). Share price has been volatile over the past 3 months (12% average weekly change). New Risk • Feb 05
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: US$9.96m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 20% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (125% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$9.96m market cap). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (US$12m net loss in 2 years). Duyuru • Jan 21
Phio Pharmaceuticals Announces Key Tumor Response Data from All Cohorts in Intratumoral PH-762 Dose Escalation Cutaneous Carcinoma Trial Phio Pharmaceuticals Corp. announced a summary of the pathology results and safety outcomes across all cohorts in its Phase 1b dose escalation clinical trial with the INTASYL compound PH-762 for the treatment of skin cancer. A total of 22 patients with cutaneous carcinomas completed treatment across five cohorts in the Phase 1b trial and underwent excision of the treated lesional site. Among the 20 patients with cSCC, 14 patients were determined to be pathologic responders, including 10 patients with complete response (100% clearance), 2 patients with major/near clear response (greater than 90% clearance), and 2 patients with partial response (greater than 50% clearance). A single patient with metastatic Merkel cell carcinoma had a partial response with greater than 50% clearance. Six cSCC patients and one melanoma patient had responses of less than 50%, however, none of the patients experienced a progression of the disease. There were no dose-limiting toxicities or clinically relevant treatment-emergent adverse effects in any patients who received intratumoral PH-762 in this trial. PH-762 has been well tolerated in all enrolled patients in each of the five dose escalating cohorts, increasing drug concentration 20-fold from the first to the final cohort. Safety data through an extended follow-up period is expected to be reported in the second quarter of 2026. The pathology data is remarkable with an overall response rate of 70%, complemented by a favorable safety data. The Phase 1b clinical trial is designed to evaluate the safety and tolerability of neoadjuvant use of Intratumoral PH-762 in Stages 1, 2 and 4 cSCC, Stage 4 melanoma, and Stage 4 Merkel cell carcinoma. Per the trial's protocol, patients received four injections of PH-762 at weekly intervals and pathologic response was assessed 2 weeks following the final injection of PH-762. Duyuru • Nov 01
Phio Pharmaceuticals Corp. Announces Appointment of David H. Deming as Lead Independent Director Phio Pharmaceuticals Corp. announced that David Deming has been appointed Lead Independent Director of the Board of Directors of Phio Pharmaceuticals. Mr. Deming brings over 30 years of experience in investment banking and asset management to his new role as Lead Independent Director. He was with JP Morgan for over 27 years, both in M&A and leading the Health Group in investment banking for his last 12 years there. Mr. Deming was appointed to the Phio Board of Directors in February 2025 and serves as a member of the Board's Nominating Committee. Duyuru • Jul 31
Phio Pharmaceuticals Corp., Annual General Meeting, Sep 11, 2025 Phio Pharmaceuticals Corp., Annual General Meeting, Sep 11, 2025. Location: meetnow.global/mvqdafw, United States Duyuru • Jun 26
Phio Pharmaceuticals Corp. Announces Positive Safety Monitoring Committee Recommendation to Advance Intratumoral Ph-762 Phio Pharmaceuticals Corp. announced that the Safety Monitoring Committee (SMC) recommended dose escalation in its Phase 1b clinical trial designed to evaluate the safety and tolerability of intratumoral (IT) PH-762 in the treatment of Stages 1, 2, and 4 cutaneous squamous cell carcinoma (cSCC), Stage 4 melanoma, and Stage 4 Merkel cell carcinoma. Five patients were enrolled in the fourth cohort of the Phase 1b clinical trial (NCT 06014086). Four of the enrolled patients were diagnosed with cSCC and one patient with Merkel cell carcinoma. As with the previous three cohorts, injections were well-tolerated and there were no dose-limiting toxicities, serious adverse events, or clinically relevant treatment-emergent adverse reactions reported. Pathology results related to the efficacy of PH-762 in the fourth cohort will be forthcoming. New Risk • Jun 05
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 16% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Earnings are forecast to decline by an average of 16% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (over 8x increase in shares outstanding). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$9.8m net loss in 2 years). Market cap is less than US$100m (US$10.0m market cap). Duyuru • Apr 10
Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Phio Pharmaceuticals Corp. announced that the Safety Monitoring Committee (SMC) recommended dose escalation in Phio's Phase 1b clinical trial (NCT 06014086) for Phio's lead product candidate, PH-762. Phio's Phase 1bclinical trial is a multi-center, dose-escalating trial designed to evaluate the safety and tolerability of neoadjuvant use of intratumoral PH-762 in cutaneous squamous cell carcinoma, melanoma, or Merkel cell carcinoma. This trial assesses the tumor response and determines the recommended dose for further study of PH-762. In the third cohort of this trial, three patients with cutaneous squamous cell carcinomas were enrolled. At Day 36 (tumor excision) in the second cohort, two patients had a complete response (100% tumor clearance), and one patient had a partial response (90% clearance). All three patients in cohort 1 and one patient in cohort 2 maintained stable disease. Duyuru • Feb 20
Phio Pharmaceuticals Corp. Appoints David H. Deming to Board of Directors Phio Pharmaceuticals Corp. announced the appointment of Mr. David H. Deming to the Phio Board of Directors, effective February 19, 2025. Mr. Deming will immediately serve as a member of the Board's Nominating Committee. Following the appointment of Mr. Deming, the Board now comprises 6 directors, 5 of whom are independent. David Deming has over 30 years of experience in investment banking and asset management. He was with JP Morgan for over 27 years in both M&A and leading the Health Group in investment banking for his last 12 years there. After leaving JP Morgan, he joined Integrated Finance Limited where he developed the SmartNest 401(k) asset allocation product which was sold to Dimensional Fund Advisors in 2010. David graduated from Hobart College with a Bachelor of Arts degree in Economics. He served on the Hobart and William Smith Colleges Board of Trustees for 15 years, serving 9 years as Chairman. Duyuru • Jan 17
Phio Pharmaceuticals Corp. has filed a Follow-on Equity Offering in the amount of $1.83 million. Phio Pharmaceuticals Corp. has filed a Follow-on Equity Offering in the amount of $1.83 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 610,000
Price\Range: $3
Discount Per Security: $0.255
Transaction Features: Registered Direct Offering Duyuru • Dec 24
Phio Pharmaceuticals Corp. has filed a Follow-on Equity Offering in the amount of $0.48 million. Phio Pharmaceuticals Corp. has filed a Follow-on Equity Offering in the amount of $0.48 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 240,000
Price\Range: $2
Discount Per Security: $0.15
Transaction Features: Registered Direct Offering New Risk • Dec 23
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 2.7% per year over the past 5 years. Shareholders have been substantially diluted in the past year (289% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$1.86m market cap). New Risk • Dec 15
New major risk - Revenue and earnings growth Earnings have declined by 2.7% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$8.1m free cash flow). Earnings have declined by 2.7% per year over the past 5 years. Shareholders have been substantially diluted in the past year (289% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$2.97m market cap). Minor Risk Share price has been volatile over the past 3 months (14% average weekly change). Price Target Changed • Aug 26
Price target decreased by 33% to US$36.00 Down from US$54.00, the current price target is provided by 1 analyst. New target price is 1,029% above last closing price of US$3.19. Stock is down 84% over the past year. The company is forecast to post a net loss per share of US$16.38 next year compared to a net loss per share of US$46.76 last year. Breakeven Date Change • Aug 26
Forecast to breakeven in 2025 The analyst covering Phio Pharmaceuticals expects the company to break even for the first time. New forecast suggests losses will reduce by 11% to 2024. The company is expected to make a profit of US$47.7m in 2025. Average annual earnings growth of 183% is required to achieve expected profit on schedule. Duyuru • Aug 02
Phio Pharmaceuticals Corp. Announces Robert M. Infarinato as New Chief Financial Officer Phio Pharmaceuticals Corp. announced the appointment of Robert M. Infarinato to the position of chief financial officer effective August 1, 2024. He will serve in the capacity of Principal Financial Officer including responsibility for accounting, finance, treasury, investor relations and administration. Mr. Infarinato comes to Phio with more than 20 years of financial and accounting leadership experience. He most recently was head of a consulting firm, advising on operational matters including the funding and IPO process. Previous positions include serving as Chairman of the Board of Trustees and Chair of the Finance Committee with Abington Health, executive Vice President and CFO of an international service company, Vice President Taxation and Corporate Controller at Rhone Poulenc Rorer, and Treasurer and Tax Manager-Europe for Pfizer. Duyuru • May 16
Phio Pharmaceuticals Corp Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation Study Phio Pharmaceuticals Corp. announced progress on its Phase 1b clinical study for their lead compound PH-762. Dosing of the first cohort of patients was completed and screening for the next dose cohort is on-going. Phio’s Phase 1b study (NCT 06014086) is a multi-center, dose-escalating clinical trial designed to evaluate the safety and tolerability of neoadjuvant use of intratumoral PH-762 in cutaneous squamous cell carcinoma, melanoma, or Merkel cell carcinoma. This study will assess the tumor response, and determine the recommended dose for further study of PH-762. Duyuru • Apr 24
Phio Pharmaceuticals Corp. Presents New Data About Its Lead Clinical Product Candidate, PH-762 Phio Pharmaceuticals Corp. announced it is presenting new data about its lead clinical product candidate, PH-762, an INTASYL compound. Preclinical studies demonstrate: PH-762 is rapidly taken up by cells and robustly silences PD-1 mRNA and protein in lymphocytes within the tumor microenvironment (TME) Intratumoral injection of murine PH-762 (mPH-762) significantly inhibits tumor growth in murine tumor models and is well tolerated mPH-762-mediated silencing of PH-762 within the TME may generate memory-specific T cells, promoting IFN-g release in the TME Studies in non-human primates demonstrate that PH-762 is well-tolerated and does not induce release of cytokines associated with cytokine release syndrome (CRS) These finding support the ongoing clinical trial of PH-762's safety and efficacy as a neoadjuvant therapy for treatment of cSCC, melanoma, or Merkel cell carcinoma The data, authored by Melissa Maxwell, Linda Mahoney, and Dr. Mary Spellman, will be presented at the American Society of Gene and Cell Therapy (ASGCT) on May 8th in Baltimore, Maryland. Duyuru • Apr 16
Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID) Phio Pharmaceuticals Corp. a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, announced it is presenting new data about its lead clinical candidate, PH-762, an INTASYL compound. The data will be presented in three posters at the annual meeting of the Society for Investigative Dermatology (SID) on May 16th in Dallas, Texas. The titles of the three posters are: INTASYL Self-delivering RNAi: a Flexible Platform to Treat Dermatological Malignancies, INTASYL PH-762: Intratumoral Immunotherapy Targeting PD-1, A Dose-Escalation Study of Intratumoral PH-762 Targeting PD-1 For Cutaneous Carcinoma. PH-762 is currently being studied in a US clinical trial to assess safety and efficacy in specific skin cancers (NCT 06014086). This open-label Phase 1 clinical study is designed to evaluate the safety and tolerability of neoadjuvant use of intratumoral PH-762 in Stages 1, 2, and 4 cutaneous squamous cell carcinoma, Stage 4 melanoma, and Stage 4 Merkel cell carcinoma. Stages 1 and 2 cSCC represent 77% of all new cSCC cases annually. Presentation Details are as follows: Title: INTASYL self-delivering RNAi: A Flexible Platform to TreatDermatological Malignancies, Abstract Number: 575, Session Title: Pharmacology and Therapeutic Development, Presenting Authors: Melissa Maxwell, Mary Spellman, Session Date/Time: May 16, 4:30-6:30pm, Location: Trinity Exhibit Hall. Title: INTASYL PH-762: Intratumoral immunotherapy targeting PD-1, Abstract Number: 576, Session Title: Pharmacology and Therapeutic Development, Presenting Authors: Melissa Maxwell, Mary Spellman, Session Date/Time: May 16, 4:30-6:30pm, Location: Trinity Exhibit Hall. Title: Intratumoral PH-762 targeting PD-1 for Cutaneous Carcinoma, Abstract Number: 283, Session Title: Clinical Research - Interventional Research, Presenting Authors: Melissa Maxwell, Mary Spellman, Session Date/Time: May 16, 4:30-6:30pm, Location: Trinity Exhibit Hall. Duyuru • Mar 23
Phio Pharmaceuticals Corp. Presents Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies Phio Pharmaceuticals Corp. announced it is presenting new data about INTASYL on March 21st. The event is scheduled to take place at the 10th Immunotherapy of Cancer Conference (ITOC10), which will be held in Munich, Germany from March 21-23, 2024. The poster, Enhancing NK cell cytotoxicity against tumor cells with a novel self-delivering RNAi compound targeting Cbl-b, reveals new preclinical data demonstrating the potential of treatment with INTASYL self-delivering siRNA Compound PH-905, formerly known as Compound 27547, to improve function of natural killer (NK) cells. The data reveals a consistent silencing of Cbl-b mRNA, which has been shown to limit NK cell activation. Cytotoxic activity of NK cells against K562 (Chronic Myelogenous Leukemia) cancer cells was also increased. By reducing the expression of Cbl-b, INTASYL promotes NK cell activation and proliferation. These preclinical data demonstrate the potential of INTASYL Compound PH-905 to improve Adoptive Cell Therapy (ACT) by targeting and silencing Cbl-b. This may result in a more effective cell therapy for hematological malignancies. INTASYL is the only self-delivering RNAi technology focused on immuno-oncology therapeutics. INTASYL drugs precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. Duyuru • Mar 14
Phio Pharmaceuticals Corp. Announces Addition of Clinical Trial Sites At Banner Md Anderson Cancer Center, the George Washington University, and Integrity Research Phio Pharmaceuticals Corp. announced the addition of three clinical trial sites for its Phase 1b study of PH-762: The George Washington University—Medical Faculty Associates in Washington, D.C. Banner MD Anderson Cancer Center in Gilbert, Arizona. Integrity Research Clinical Associates in Delray Beach, Florida. PH-762 is an INTASYL compound that silences PD-1, a protein that inhibits T cells’ ability to kill cancer cells. The Phase 1b trial is a non-comparative study of neoadjuvant monotherapy using PH-762 in adult patients with cutaneous squamous cell carcinoma, melanoma, or Merkel cell carcinoma. The study is designed to evaluate the safety and tolerability of neoadjuvant use of intratumorally injected PH-762, assess the tumor response, and determine the dose or dose range for continued study of PH-762 in patients with cutaneous squamous cell carcinoma, melanoma, or Merkel cell carcinoma. Duyuru • Mar 07
Phio Pharmaceuticals Corp. Announces Patent Granted by Uspto, Strengthening the Company's Intellectual Property Position in Treating Aging Skin and Skin Disorders Phio Pharmaceuticals Corp. announced that the United States Patent and Trademark Office (USPTO) has granted patent application 17/150,614 for two of its INTASYL Compounds, RXI-185 and RXI-231. The compounds treat age-related skin disorders including photo-aging and dermal hyperpigmentation, targeting the down-regulation of the Matrix metalloproteinase-1 (MMP1) and Tyrosinase (TYR) proteins. Ultraviolet radiation (UVR) exposure is a known contributor to skin cancer and aging, inducing the hyperactivity of MMP1 which increases collagen breakdown and reduces collagen synthesis. RXI-185 is a potent silencer of MMP1 expression in the skin, interrupting UVR induced collagen breakdown, thereby, improving and/or slowing the progression for skin thickening, elasticity and wrinkles. Various dermal pigmentation conditions including melasma and lentigines are notoriously difficult to treat. RXI-231 has been shown to penetrate the epidermal-dermal junction where tyrosinase-producing melanocytes reside and reduces the levels of tyrosinase (TYR). The Phio patent portfolio now consists of 81 issued patents, 77 of which cover its INTASYL siRNA gene silencing technology. INTASYL drugs precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. Duyuru • Jan 27
Phio Pharmaceuticals Receives Non-Compliance Notice from Nasdaq On January 24, 2024, Phio Pharmaceuticals Corp. (the “Company”) received written notice (the “Notification Letter”) from The Nasdaq Capital Market (“Nasdaq”) stating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Rule”) because the Company’s common stock failed to maintain a minimum closing bid price of $1.00 for 30 consecutive business days. The Notice has no immediate effect on the Nasdaq listing or trading of the Company’s common stock. The Notification Letter provides an initial 180 calendar day period, or until July 22, 2024, in which to regain compliance, pursuant to Listing Rule 5810(c)(3)(A). If, at any time before that date the bid price of the Company’s common stock closes at $1.00 per share or more for a minimum of 10 consecutive business days, Nasdaq will notify the Company that it has achieved compliance with the Minimum Bid Price Rule. The Company intends to actively monitor the closing bid price of its common stock and will evaluate available options to regain compliance with the Minimum Bid Price Rule. Duyuru • Nov 10
Phio Pharmaceuticals Corp. Announces First US Patient Enrolled in Phase 1B Clinical Trial with Intratumoral PH-762 anti-PD-1 Therapy for Treatment of Skin Carcinomas Phio Pharmaceuticals Corp. announced that the first patient has been dosed in the Phase 1b clinical trial of PH-762, an INTASYL compound that reduces the expression of PD-1, a protein that inhibits T cells’ ability to kill cancer cells. This clinical trial is designed to evaluate the safety and tolerability of neoadjuvant use of intratumorally injected PH-762, assess the tumor response, and determine the dose or dose range for continued study of PH-762 in patients with cutaneous squamous cell carcinoma, melanoma, or Merkel cell carcinoma. The Phase 1b trial is a non-comparative study of neoadjuvant monotherapy using PH-762 in adult patients with cutaneous squamous cell carcinoma, melanoma, or Merkel cell carcinoma. The study treatment consists of four intratumoral injections of PH-762 at weekly intervals within a single tumor lesion. Excision of the tumor occurs approximately two weeks following the fourth intratumoral dose of PH-762. Escalating doses of PH-762 are to be tested in separate cohorts. The clinical study is expected to enroll up to 30 patients and will be conducted across 4 to 6 centers in the United States. Duyuru • Nov 04
Phio Pharmaceuticals Corp. Announces the Presentation of New Preclinical Data At the 38Th Annual Meeting of the Society for Immunotherapy of Cancer Phio Pharmaceuticals Corp. announced the presentation of new preclinical data at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). The event is scheduled to take place in San Diego, California, from November 1-5, 2023. Phio’s innovative preclinical study data highlights the benefit of intratumoral injection (IT) of an INTASYL compound targeting CTLA-4 (27790) in conjunction with systemic anti-PD-1 antibody therapy. Preclinical studies have demonstrated: The combination of INTASYL compound 27790 with systemic anti-PD-1 antibody therapy significantly enhanced the efficacy of anti-PD-1 mAb therapy in vivo. The combination of INTASYL compound 27790 and anti-PD-1 elicited complete regression of ~40% of IT treated tumors in a mouse model. Additionally, INTASYL compound 27790 appeared to improve the efficacy of anti-PD-1 therapy toward those tumors not treated directly with 27790. INTASYL compound 27790 increased the percentage of reactive CD8+ T cells in the tumor while decreasing immunosuppressive/pro-tumor macrophages in the treated tumor micro-environment. Duyuru • Oct 12
Phio Pharmaceuticals Corp. Presents New Data for Targeting of BRD4 with its INTASYL Compound PH-894 Phio Pharmaceuticals Corp. announced the poster presentation of two key preclinical studies of its INTASYL compound PH-894 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts on October 11th -15th. The first study shows that melanoma cells treated with its PH-894 compound makes them more recognizable to the immune cells. Specifically, the treatment results in an increase in the tumor marker MART-1 (Melanoma tumor-associated antigen) allowing for better recognition and potentially increased killing by T cells. Local treatment with PH-894 presents a strategy to decrease BRD4 expression and upregulate MART-1 expression to increase immune response to cancer cells while reducing toxicities associated with systemic therapies. This study supports further development of PH-894 for injectable solid tumor indications such as melanoma. The second study demonstrates the effectiveness of PH-894 as an antitumor cytotoxic agent (directly killing tumor cells). The addition of PH-894 to cells in vitro elicited concentration-associated apoptosis of all human cancer cell lines tested, including head and neck squamous cell carcinoma (HNSCC), hepatocellular carcinoma (HCC), breast cancer, lung cancer, glioblastoma, melanoma, colon cancer, ovarian cancer, and cervical cancer. INTASYL PH-894, a precision self-delivering RNAi therapy, is administered locally and is designed to provide a novel, safer strategy to realize the enormous therapeutic potential of BRD4 inhibition for cancer that has been difficult to attain for small molecule modalities that rely on systemic approaches that generate significant toxicity. Duyuru • Aug 22
Phio Pharmaceuticals Corp. Announces Dosing of First Patient in Collaborative Clinical Trial with Agonox, Inc. and Providence Cancer Institute Phio Pharmaceuticals Corp. announced that its clinical development partners, AgonOx Inc. and Providence Cancer Institute of Oregon, have dosed their first patient in an Adoptive Cell Therapy clinical trial. This first-in-human trial is investigating the safety and the potential for enhanced therapeutic benefit from the administration of AgonOx’s AGX148 'double positive' (DP) CD8 tumor-infiltrating lymphocytes (TIL) alone and in combination with Phio's PD-1 silencing PH-762 in patients with melanoma and other advanced solid tumors. More information about this clinical trial is available at clinicaltrials.gov. The clinical trial is one of two studies cleared by the FDA which will utilize Phio’s lead product candidate, PH-762. Duyuru • Jun 10
Phio Pharmaceuticals Corp., Annual General Meeting, Jul 20, 2023 Phio Pharmaceuticals Corp., Annual General Meeting, Jul 20, 2023, at 09:00 US Eastern Standard Time. Agenda: To consider Election of Directors; to consider Ratification of BDO USA, LLP as our independent registered public accounting firm for the fiscal year ending December 31 , 2023; to approve an amendment and restatement of the 2020 Phio Pharmaceuticals Corp . Long Term Incentive Plan to increase the number of shares of common stock available for issuance; and to transact such other business matter. Duyuru • Jun 02
Phio Pharmaceuticals Corp. announced that it expects to receive $3.000002 million in funding Phio Pharmaceuticals Corp. announced that it has entered into definitive agreements to issue 700,935 shares at a price of $4.28 per share for gross proceeds of $3,000,002, unregistered series A warrants to purchase up to an aggregate of 934,581 shares of common stock and unregistered series B warrants to purchase up to an aggregate of 934,581 shares of common stock on May 31, 2023. Each series of warrants will have an exercise price $4.03 per share and become exercisable immediately upon issuance. The Series A warrants have a term of five and one-half years from the date of issuance and the Series B warrants have a term of eighteen months from the date of issuance. The company will issue securities pursuant to exemption provided under regulation D. The transaction is expected to close on or about June 2, 2023, subject to the satisfaction of customary closing conditions. Duyuru • May 19
Phio Pharmaceuticals Corp Presents Preclinical Study Showing INTASYL Treatment of NK Cells More than Doubles Ability to Kill Tumor Cells Phio Pharmaceuticals Corp. announced pre-clinical data demonstrating that using INTASYL to silence TIGIT and CBL-B may be used to improve the anti-tumor response of NK cells, creating a more effective cell therapy for treating cancer. NK cells are the body's first line of defense against cancer. Unlike T cells, NK cells can recognize and kill tumor cells without prior exposure. Incorporating INTASYL's RNAi treatment into ex vivo NK cell expansion protocols prior to adoptive cell therapy (ACT) is a strategy to reduce the expression of inhibitory proteins such as TIGIT or CBL-B to improve anti-tumor response. Duyuru • May 17
Phio Pharmaceuticals Announces FDA Clearance to Initiate Clinical Trial of PH-762 for Treatment of Skin Carcinomas Phio Pharmaceuticals Corp. announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application to proceed with a clinical trial of Phio's lead product candidate, PH-762. PH-762 is an INTASYL compound that reduces the expression of PD-1, a protein that inhibits T cells' ability to kill cancer cells. Phio plans to initiate its Phase 1b clinical trial of intratumoral PH-762 in patients with cutaneous squamous cell carcinoma, melanoma and Merkel cell in the second half of 2023. The initial multi-center, dose-escalating, Phase 1b clinical trial under Phio's cleared IND is designed to evaluate the safety and tolerability of neoadjuvant use of intratumorally injected PH-762, assess the tumor response, and determine the dose or dose range for continued study of PH-762. Phio will focus its efforts on the U.S. clinical trial and intends to wind down its first-in-human clinical trial for PH-762 in France, which was limited to the treatment of patients with metastatic melanoma. PH-762 has also received clearance to proceed under an IND sponsored by AgonOx Inc. in a clinical trial evaluating PH-762 treated "double positive" (DP) CD8 tumor infiltrating lymphocytes (TIL) in patients with melanoma and other advanced solid tumors. Duyuru • Feb 14
Phio Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements On February 13, 2023, Phio Pharmaceuticals Corp. announced that it has received a letter from The Nasdaq Stock Market LLC advising the Company that it has regained compliance with Nasdaq's minimum bid price listing requirement. Phio has satisfied the terms of the Nasdaq Listing Qualifications Panel by complying with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2), and all other criteria for continued listing. Accordingly, Nasdaq has advised that the matter is now closed. Duyuru • Feb 11
Phio Pharmaceuticals Corp. Announces Positive DMC Recommendation and Continued Enrollment of Advanced Melanoma Study Without Modification Phio Pharmaceuticals Corp. announced that an independent Data Monitoring Committee (DMC) completed its prespecified review of interim safety data in the Company's Phase 1b clinical trial of PH-762 for the treatment of advanced melanoma. The trial is ongoing at the Gustave Roussy Institute (Villejuif, France). PH-762 is an INTASYL compound that reduces the expression of cell death Protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells. Decreasing the expression of PD-1 increases the capacity of T cells to kill cancer cells. Following completion of the treatment period through excision of the tumor, safety data from the initial cohort of three subjects in the Phase 1 trial was evaluated by the DMC. The safety data review disclosed no dose-limiting toxicity, and no drug-related severe adverse events or serious adverse events, and the DMC recommended proceeding to the enrollment of the subsequent dose cohort, as intended per the study protocol. In addition to the Phase 1b study in France, Phio expects to commence a US Phase 1b clinical trial focusing on the treatment of cutaneous squamous cell carcinoma (cSCC) and other selected cutaneous malignancies, early in the 2nd half of 2023. Price Target Changed • Apr 27
Price target decreased to US$6.00 Down from US$138, the current price target is provided by 1 analyst. New target price is 532% above last closing price of US$0.95. Stock is down 61% over the past year. The company is forecast to post earnings per share of US$0.89 next year compared to a net loss per share of US$1.04 last year. Price Target Changed • Dec 06
Price target decreased to US$6.00 Down from US$138, the current price target is provided by 1 analyst. New target price is 408% above last closing price of US$1.18. Stock is down 51% over the past year. The company is forecast to post a net loss per share of US$1.11 next year compared to a net loss per share of US$1.92 last year.